CN118525004A - 用于治疗高血糖症和2型糖尿病的结晶形式的(r)-2-(叔丁氨基)-1-(5-氟吡啶-3-基)-乙-1-醇半酒石酸盐 - Google Patents

用于治疗高血糖症和2型糖尿病的结晶形式的(r)-2-(叔丁氨基)-1-(5-氟吡啶-3-基)-乙-1-醇半酒石酸盐 Download PDF

Info

Publication number
CN118525004A
CN118525004A CN202280081693.4A CN202280081693A CN118525004A CN 118525004 A CN118525004 A CN 118525004A CN 202280081693 A CN202280081693 A CN 202280081693A CN 118525004 A CN118525004 A CN 118525004A
Authority
CN
China
Prior art keywords
salt
hyperglycemia
treatment
diabetes
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280081693.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·佩尔卡曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atoki
Original Assignee
Atoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atoki filed Critical Atoki
Publication of CN118525004A publication Critical patent/CN118525004A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280081693.4A 2021-12-09 2022-12-09 用于治疗高血糖症和2型糖尿病的结晶形式的(r)-2-(叔丁氨基)-1-(5-氟吡啶-3-基)-乙-1-醇半酒石酸盐 Pending CN118525004A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2117828.0A GB2613616A (en) 2021-12-09 2021-12-09 New formulations
GB2117828.0 2021-12-09
PCT/EP2022/085133 WO2023105035A1 (en) 2021-12-09 2022-12-09 Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2

Publications (1)

Publication Number Publication Date
CN118525004A true CN118525004A (zh) 2024-08-20

Family

ID=80079964

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280081693.4A Pending CN118525004A (zh) 2021-12-09 2022-12-09 用于治疗高血糖症和2型糖尿病的结晶形式的(r)-2-(叔丁氨基)-1-(5-氟吡啶-3-基)-乙-1-醇半酒石酸盐

Country Status (11)

Country Link
US (1) US20250042856A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444699A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024544698A (cg-RX-API-DMAC7.html)
KR (1) KR20240116482A (cg-RX-API-DMAC7.html)
CN (1) CN118525004A (cg-RX-API-DMAC7.html)
AU (1) AU2022405700A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241501A1 (cg-RX-API-DMAC7.html)
GB (1) GB2613616A (cg-RX-API-DMAC7.html)
IL (1) IL313292A (cg-RX-API-DMAC7.html)
MX (1) MX2024006960A (cg-RX-API-DMAC7.html)
WO (1) WO2023105035A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120583945A (zh) 2023-01-20 2025-09-02 阿托基公司 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂
GB202303229D0 (en) * 2023-03-06 2023-04-19 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Also Published As

Publication number Publication date
WO2023105035A1 (en) 2023-06-15
US20250042856A1 (en) 2025-02-06
KR20240116482A (ko) 2024-07-29
AU2022405700A1 (en) 2024-06-20
GB202117828D0 (en) 2022-01-26
EP4444699A1 (en) 2024-10-16
JP2024544698A (ja) 2024-12-03
CA3241501A1 (en) 2023-06-15
IL313292A (en) 2024-08-01
GB2613616A (en) 2023-06-14
MX2024006960A (es) 2024-06-24

Similar Documents

Publication Publication Date Title
US12280023B2 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
EP3681872B1 (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US20250042856A1 (en) Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2
JP7346388B2 (ja) ベータ-ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用
US11793774B2 (en) Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
TWI848911B (zh) 以三唑并吡啶治療rbp4相關疾病之方法
CN113784953A (zh) 可用于治疗高血糖症的杂环基(苯基)甲醇化合物
TW201105336A (en) Combined medicine of pyrazole derivative and biguanide drug
JP2022525948A (ja) 高血糖症の治療に有用なヘテロアリール(ヘテロシクリル)メタノール化合物
US20260001872A1 (en) Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof
WO2025186320A1 (en) Combinations of beta 2-adrenergic receptor agonists and sglt2 inhibitors for use in treating hyperglycaemia or a disorder characterized by hyperglycaemia
CN121001724A (zh) 用于治疗高血糖症的β-2-肾上腺素能受体激动剂与GLP-1受体激动剂的组合
BR112020005045B1 (pt) Composição farmacêutica compreendendo betahidroxietilaminas de fluorofenila, seu uso e kit de partes para o tratamento de hiperglicemia ou um distúrbio tendo hiperglicemia como um sintoma
HK40033371B (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
HK40033371A (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination